Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders

Hanif, Sumaira; Muhammad, Pir; Niu, Zheng; Morsch, Marco; Li, Mingqiang; Shi, Bingyang

doi:10.1002/anbr.202100008

Cited by 21 publications

(10 citation statements)

References 334 publications

(329 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, nano-biosensors and molecular probes have been developed in the field of biomarkers detection and molecular imaging with the aim of AD diagnosis ( Kaushik et al, 2016 ; Jun et al, 2019 ; Yang et al, 2019 ; Bilal et al, 2020 ; Hanif et al, 2021 ). Due to the inherent characteristics of a high surface-area-to-volume ratio, targeting ligand surface modification and higher blood-brain barrier (BBB) permeability, nanomaterials have great potential in fast, selective and sensitive detection of biomarker ( Gopalan et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer’s Disease in Blood

Guo

Wang

2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases with irreversible damage of the brain and a continuous pathophysiological process. Early detection and accurate diagnosis are essential for the early intervention of AD. Precise detection of blood biomarkers related to AD could provide a shortcut to identifying early-stage patients before symptoms. In recent years, targeting peptides or peptoids have been chosen as recognition elements in nano-sensors or fluorescence detection to increase the targeting specificity, while peptide-based probes were also developed considering their specific advantages. Peptide-based sensors and probes have been developed according to different strategies, such as natural receptors, high-throughput screening, or artificial design for AD detection. This review will briefly summarize the recent developments and trends of AD diagnosis platforms based on peptide and peptoid as recognition elements and provide insights into the application of peptide and peptoid with different sources and characteristics in the diagnosis of AD biomarkers.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer’s Disease in Blood

Guo

Wang

2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“… 56 Nanoparticles are being used to capture cancer biomarkers including cancer-associated proteins, 57 , 58 circulating tumor DNA (ctDNA), 59 , 60 circulating tumor cells (CTC), and exosomes. 61 , 62 Antibodies, small molecules, peptides, aptamers, and other compounds can be thickly coated on nanoparticle surfaces because of this high surface area-to-volume ratio. Multivalent effects can be obtained by presenting multiple binding ligands to cancer cells, which can improve the specificity and sensitivity of diagnosis.…”

Section: Application Of Nanotechnology For Cancer Diagnosis and Treat...mentioning

confidence: 99%

Section: Nanotechnology For Cancer Diagnosismentioning

confidence: 99%

Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis

Dessale¹,

Mengistu²,

Mengist³

2022

IJN

View full text Add to dashboard Cite

Cancer remains the most devastating disease and the major cause of mortality worldwide. Although early diagnosis and treatment are the key approach in fighting against cancer, the available conventional diagnostic and therapeutic methods are not efficient. Besides, ineffective cancer cell selectivity and toxicity of traditional chemotherapy remain the most significant challenge. These limitations entail the need for the development of both safe and effective cancer diagnosis and treatment options. Due to its robust application, nanotechnology could be a promising method for in-vivo imaging and detection of cancer cells and cancer biomarkers. Nanotechnology could provide a quick, safe, cost-effective, and efficient method for cancer management. It also provides simultaneous diagnosis and treatment of cancer using nano-theragnostic particles that facilitate early detection and selective destruction of cancer cells. Updated and recent discussions are important for selecting the best cancer diagnosis, treatment, and management options, and new insights on designing effective protocols are utmost important. This review discusses the application of nanotechnology in cancer diagnosis, therapeutics, and theragnosis and provides future perspectives in the field.

show abstract

“…On the other hand, the FDA-approved 30-nm magnetic nanoparticles (MNPs) have been used to predict the co-localization of therapeutic nanoparticles (NPs) with tumors by MRI, and changes in mean T2 mapping are utilized to quantify MNP levels [6]. In addition to MRI, computed tomography (CT), positron emission tomography (PET), single photon emission CT (SPECT), fluorescence imaging (FI), photoacoustic imaging (PAI), and Raman imaging have already been utilized to detect GBM [7,8]. As with MRI, CT provides anatomical structure information [9,10].…”

Section: Introductionmentioning

confidence: 99%

Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma

Zhuang

Zhang

2022

J Nanobiotechnol

View full text Add to dashboard Cite

Glioblastoma (GBM) as the most common primary malignant brain tumor exhibits a high incidence and degree of malignancy as well as poor prognosis. Due to the existence of formidable blood–brain barrier (BBB) and the aggressive growth and infiltrating nature of GBM, timely diagnosis and treatment of GBM is still very challenging. Among different imaging modalities, magnetic resonance imaging (MRI) with merits including high soft tissue resolution, non-invasiveness and non-limited penetration depth has become the preferred tool for GBM diagnosis. Furthermore, multimodal imaging with combination of MRI and other imaging modalities would not only synergistically integrate the pros, but also overcome the certain limitation in each imaging modality, offering more accurate morphological and pathophysiological information of brain tumors. Since contrast agents contribute to amplify imaging signal output for unambiguous pin-pointing of tumors, tremendous efforts have been devoted to advances of contrast agents for MRI and multimodal imaging. Herein, we put special focus on summary of the most recent advances of not only MRI contrast agents including iron oxide-, manganese (Mn)-, gadolinium (Gd)-, 19F- and copper (Cu)-incorporated nanoplatforms for GBM imaging, but also dual-modal or triple-modal nanoprobes. Furthermore, potential obstacles and perspectives for future research and clinical translation of these contrast agents are discussed. We hope this review provides insights for scientists and students with interest in this area. Graphical abstract

show abstract

Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders

Cited by 21 publications

References 334 publications

Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer’s Disease in Blood

Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer’s Disease in Blood

Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis

Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma

Contact Info

Product

Resources

About